The ISIDORe II project invites applications for free-of-charge Transnational Access (TNA) to research infrastructure services supporting Andes virus (ANDV) and ANDV-relevant hantavirus research.
Applications should address one or more of the priority areas below and must request access to one or more services available through the ISIDORe II catalogue of services. Applicants should identify the main priority area addressed by their proposal and explain why the requested ISIDORe II service, or combination of services, is needed.
Applicants are encouraged to download the full call text before applying, as it includes the detailed scope, eligibility conditions and application requirements.
Eligibility of applicants
The call is open to researchers from academia, public research organisations, public-health-linked research bodies, industry, SMEs and all relevant research-performing organisations. Priority will be given to applicants that did not receive support under the first ISIDORe grant.
Access will be provided according to Horizon Europe TNA rules. At least 80% of access provision must benefit users from EU Member States or countries associated to Horizon Europe, while up to 20% may support international users where justified and eligible under ISIDORe II rules.
Applicants must comply with all relevant ethical, biosafety, biosecurity, data protection, access, reporting and visibility requirements.
PRIORITY AREAS
THerapeutic and non-vaccine prophylactic candidate evaluation
This area covers proposals seeking service-based evaluation, comparison or characterisation of existing therapeutic or non-vaccine prophylactic candidates against ANDV or ANDV‑relevant hantaviruses.
Priority will be given to proposals that use ISIDORe II services to generate additional preclinical or translationally relevant evidence on existing candidates.
Diagnostic tools, assays, reagents and reference materials for ANDV-relevant research
This area covers proposals seeking service-based development, adaptation, analytical evaluation, benchmarking or characterisation of diagnostic tools, assays, reagents, reference materials or related research tools for ANDV or ANDV-relevant hantaviruses.
Priority will be given to proposals that address a specific gap in ANDV-related diagnostic or assay readiness, such as analytical sensitivity, specificity, cross-reactivity, robustness, portability, standardisation, or access to appropriate controls, panels, sera, antibodies, recombinant proteins or viral material.
ANDV-relevant models, experimental systems and readouts
This area covers proposals seeking service-based use, comparison or characterisation of models, experimental approaches or readouts for ANDV or ANDV-relevant hantavirus research.
Priority will be given to proposals that help determine whether a model, system or readout is suitable for a defined ANDV-relevant purpose, such as pathogenesis studies, tropism studies, host-response analysis or research on medical countermeasures.
SERVICES
Analytical services
Types of services
| RT- PCR design |
| NGS from isolates or animal/human samples |
| Whole-genome sequencing of ANDV |
Clinical research support
Types of services
| Advice for planning and design of hantavirus preparedness studies in humans | Trainings and capacity building |
| Regulatory/ethical advice support for hantavirus preparedness studies in humans | Data deposition services in clinical research Data Sharing Repository (crDSR) |
Drug Discovery
Types of services
| High-throughput ANDV antiviral compound screening (multiple platforms) |
| ANDV antiviral hit validation in physiologically relevant human models |
| Antiviral hit discovery and hit-to-lead support for hantavirus |
| Hantavirus mAb affinity characterization |
| Acoustic ejection – Mass spectrometry |
Ex vivo models
Types of services
| Human brain organoids | Hamster lung-slice |
| Human trophoblast organoids | Hamster lung organoids |
| Human placenta explants | Virus isolation from human and animal samples |
| Human airway epithelial cells at the air-liquid interface | Andes and related hantaviruses in cellulo pathophysiology |
| Precision-cut lung slices | Andes and related hantaviruses antiviral assays |
| Endothelial cell models | Hantavirus neutralisation assays with live virus and pseudovirus |
| Human 3D vessel |
Imaging services
| Optical and intravital imaging | X-Ray microCT |
| MRI | Super-resolution fluorescence microscopy (nanoscopy) |
| Phase contrast imaging | Cryo-electron microscopy |
| Bioluminescence/fluorescence imaging | Volume electron microscopy |
| MALDI Mass spectrometry imaging | Image analysis |
Immunomonitoring and profiling
| Hantavirus cellular immune assay |
| Adjuvant formulation service |
| Production of proteins, nanoparticles, VLPs, viral vectors |
| Process development, scale-up and tech transfer |
| Bioanalytics |
In vivo models
| In vivo pathogenicity studies in mice | In vivo high throughput preclinical pipeline |
| Hantavirus assays in mouse lung xenograft model | In vivo drug efficacy studies |
| Hamster infection model | Vaccine research, discovery, immunogenicity and efficacy evaluation in NHP |
| Immunogenicity of vaccine formulations, including mRNA vaccines | Pathogen-host interaction studies in NHP |
Reference materials
| Hantavirus live strains for research |
| Hantavirus live isolates biobanking |
| Seoul virus strain provision |
Regulatory advice
Regulatory Advice and Development Strategy
Structural biology
| Electron microscopy (including TEM, cryoEM, cryoET, FIB-SEM) for pathogen characterisation (eg:Hantavirus) | Protein and RNA production (bacteria, insect and mammalian cells) |
| Support for EM data analysis collected on pathogens (eg:Hantavirus) | X-ray technology (MX, SAXS) for virus and protein complexes characterisation |
| Mass spectrometry (native MS, proteomic MS,HDX) for Identification, characterisation and host/pathogen interaction studies | Crystallisation for structural characterisation of pathogens |
| Nanobody discovery | Imaging & nanobiotechnology for structural biology |
| Magnetic resonance technology (ssNMR, solutionNMR, EPR…) for pathogen (eg: Hantavirus) characterisation and biomarkers studies | Fragment screening for drug discovery |
| Structural biology data interpretation support | Molecular biophysics (CD, MALS, AFM, SPR, BLI…) for identification, characterisation and host/pathogen interaction studies |
Vaccine Development
Supply of (possibly GMP) adjuvant for toxicological and clinical studies
In vitro evaluation of mRNA vaccines
how to apply
- Please make sure that you have read (and comply with) the call criteria and eligibility conditions.
- Prepare your ORCID number. If you do not have one yet, please go to orcid.org to obtain your own in a few clicks.
- Select the service you want to apply for from our catalogue.
- Follow the prompts to login or create a new profile in the ISIDORe Access Management System (AMS)
- You will be asked to fill in and submit your pre-application form briefly describing your research proposal.
- After your pre-application is submitted, you will receive an ISIDORe ID number (ISID_xxxx). Please ensure that you include this ID number in all future enquiries regarding your application and service provision.
- You will receive follow up instructions from the relevant ISIDORe partner for how to submit your full application.
- Depending on the service request details, you may be asked to provide further information regarding ethical and security aspects.
- Your application will be first evaluated for compliance with eligibility criteria, then reviewed for feasibility and peer reviewed by an independent panel of external evaluators. You will be notified of the outcome.
- Successful applicants will be contacted by ISIDORe and will then agree on the next steps and timeline for implementation in the laboratory identified as the most appropriate for your service request. Users of ISIDORe services will be required to agree to our terms and conditions of service before service provision begins.